Best Peptides for Healing & Injury Recovery: A Ranked Guide
Which peptides support tissue healing and injury recovery — ranked by evidence, with the type of injuries each works best for, common reference dose ranges, and honest caveats.
No peptide class is more studied for tissue healing than BPC-157 and TB-500 (Thymosin Beta-4). Both work through complementary mechanisms — BPC-157 acts locally and systemically via nitric oxide pathways, growth factor receptor upregulation, and angiogenesis promotion, while TB-500 drives cell migration, actin binding, and systemic regeneration at a larger scale. Growth hormone secretagogues support the overnight repair process through GH pulsatility. Understanding which compound fits which injury type is the key to using this category effectively.
Most evidence for BPC-157 and TB-500 comes from animal studies. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies: 35 preclinical and 1 small human case series, and concluded human safety and effectiveness are not yet established [1].
This guide focuses specifically on healing and recovery evidence — not general wellness. Evidence grades are based on available preclinical and human data. Most healing peptides have Grade C evidence (animal studies), reflecting the difficulty of conducting RCTs for musculoskeletal injuries, not necessarily a lack of real-world efficacy.
Evidence Grade Key
⚠ Medical disclaimer: Research peptides discussed here are not FDA-approved for the uses described (exceptions noted). All dosing figures are common reference ranges from research and community literature — not medical prescriptions. Always discuss any compound protocol with a qualified healthcare provider before starting.
Ranked by Evidence
BPC-157
Grade CHealing & Recovery · Gut Health
The most researched peptide for acute tissue healing — tendons, ligaments, muscle, gut lining, and nerve repair all studied in preclinical models.
BPC-157 is a pentadecapeptide derived from a protective gastric juice protein. It promotes healing through multiple pathways: upregulation of growth factor receptors (EGF, VEGF, FGF), enhanced angiogenesis (new blood vessel formation at injury sites), modulation of the nitric oxide system, and collagen fiber organization. Its unique property is acting both locally (at injection or oral delivery site) and systemically. In rat studies, BPC-157 improved healing of tendon, ligament, muscle and gut injuries [1][2]; whether this holds in people is unknown.
Reference Dose Range
250–500 mcg/day
Oral works well for gut healing; subcutaneous or intramuscular injection near injury site for musculoskeletal.
Route
Subcutaneous or Oral
Best for
Studied in animal models of tendon, ligament, muscle, gut and nerve injury.
Caveat
Grade C — primarily animal models. Significant angiogenic activity is a theoretical concern for individuals with active malignancy. No large-scale human RCTs exist yet. The only published human orthopaedic report is a small retrospective series of knee injections without a control group [3]. Not FDA-approved. In July 2026 an FDA advisory committee voted 8–6 to recommend allowing compounding pharmacies to prepare BPC-157; the vote is non-binding and FDA has not finalized it [4]. Prohibited in sport by WADA [1][5].
TB-500 (Thymosin Beta-4)
Grade CHealing & Recovery · Systemic Repair
Systemic tissue repair and regeneration — best for larger injuries, muscle tears, and widespread inflammation where a localized approach isn't enough.
TB-500 is a short synthetic fragment of thymosin beta-4. In rats, thymosin beta-4 accelerated wound healing [6]. It binds to actin, promotes cell migration to injury sites, stimulates new blood vessel growth, and regulates the inflammatory response during healing. Unlike BPC-157, which can be injected locally, TB-500's mechanism is inherently systemic — making it better suited to large injuries, full-body recovery, or chronic inflammation.
Reference Dose Range
2–5 mg/week (loading), then 2–2.5 mg/week (maintenance)
Common protocol: 2–5 mg/week for 4–6 weeks loading phase, then 2 mg every 1–2 weeks.
Route
Subcutaneous
Best for
Muscle tears, widespread joint inflammation, slow-healing injuries, or as a systemic layer alongside BPC-157 for complex injuries.
Caveat
Higher per-dose cost than BPC-157. Same theoretical malignancy concern applies given angiogenic activity. Grade C reflects animal data; FDA says it has not identified human exposure data for TB-500 [7]. The same July 2026 advisory vote (8–6, non-binding) covered TB-500 [4]. Prohibited in sport by WADA [5].
BPC-157 + TB-500 Blend
Grade CHealing & Recovery · Combined
The most popular healing stack — local and systemic repair mechanisms working simultaneously.
Stacking BPC-157 and TB-500 combines BPC-157's local tissue effects and gut healing properties with TB-500's systemic cell migration and angiogenesis promotion. The two mechanisms are complementary rather than redundant: BPC-157 supports the growth factor and nitric oxide environment at the local level, while TB-500 drives systemic cell recruitment and inflammatory modulation. This combination is widely used in the research community for complex or slow-healing injuries.
Reference Dose Range
250–500 mcg BPC-157 + 2–2.5 mg TB-500 per dose
Can be mixed in the same syringe if both are reconstituted in BAC water. Use the reconstitution calculator for accurate dosing.
Route
Subcutaneous
Best for
Complex injuries involving both local tissue damage and systemic inflammation, or where a faster return to training is the goal.
Caveat
No combination-specific human trial data. Evidence is extrapolated from individual compound studies. The blend is mechanistically rational, not proven in RCTs. No studies have tested BPC-157 and TB-500 together; the combination rationale is theoretical.
Ipamorelin
Grade CGH Secretagogue · Recovery & Sleep
The cleanest GH secretagogue for recovery — generates a natural GH pulse at bedtime with no cortisol spike or significant hunger increase.
Ipamorelin is a selective GHRP (growth hormone releasing peptide) that stimulates pituitary GH release without affecting cortisol, prolactin, or ACTH — side effects common with older GHRPs. GH is critical for tissue repair: it drives protein synthesis, stimulates IGF-1 (which promotes cellular proliferation and repair), and supports the restorative processes that occur primarily during slow-wave sleep. A bedtime injection aligns with the body's natural overnight GH pulse. In animal studies ipamorelin released GH without raising ACTH or cortisol [8].
Reference Dose Range
100–300 mcg per dose
Most important dose is at bedtime. Fasted dosing (2+ hours after last meal) maximizes GH pulse.
Route
Subcutaneous (2–3x/day)
Best for
Athletes in active recovery, post-injury and post-surgical recovery, improving sleep quality during healing, or as part of a GH secretagogue stack with MOD-GRF 1-29.
MOD-GRF (1-29) / CJC-1295 No DAC
Grade EGHRH Analog · Recovery & Muscle
Pairs with Ipamorelin for a synergistic GH pulse — combines GHRH + GHRP for dramatically amplified overnight GH release.
MOD-GRF (1-29), also known as CJC-1295 without DAC, is a modified GHRH analog that signals the pituitary to release GH in response to the natural GHRH pulse. When combined with Ipamorelin, it triggers GH release through two distinct mechanisms simultaneously (GHRH pathway + GHRP pathway), producing a synergistic GH pulse significantly larger than either compound alone. This amplified GH pulse drives faster recovery and tissue repair overnight.
Reference Dose Range
100–300 mcg per dose
Best taken 30–60 minutes before bed, alongside Ipamorelin, on an empty stomach.
Route
Subcutaneous (typically paired 1:1 with Ipamorelin)
Best for
Anyone using Ipamorelin for recovery who wants to maximize the overnight GH pulse. Particularly useful for athletes or those with longer healing timelines.
Quick Comparison
All dose figures are educational reference ranges — not prescriptions.
| Compound | Grade | Reference Dose | Route |
|---|---|---|---|
| BPC-157 | C | 250–500 mcg/day | Subcutaneous or Oral |
| TB-500 (Thymosin Beta-4) | C | 2–5 mg/week (loading), then 2–2.5 mg/week (maintenance) | Subcutaneous |
| BPC-157 + TB-500 Blend | C | 250–500 mcg BPC-157 + 2–2.5 mg TB-500 per dose | Subcutaneous |
| Ipamorelin | C | 100–300 mcg per dose | Subcutaneous (2–3x/day) |
| MOD-GRF (1-29) / CJC-1295 No DAC | E | 100–300 mcg per dose | Subcutaneous (typically paired 1:1 with Ipamorelin) |
Conclusion
For most injury recovery goals, BPC-157 is the first compound to consider — it has the broadest preclinical evidence, a good safety profile, and works via oral or injection routes. TB-500 adds systemic reach for larger or more complex injuries. The combination of both is the most commonly used healing stack in the research community. Adding Ipamorelin (and optionally MOD-GRF 1-29) at bedtime layers in GH-driven overnight repair — particularly valuable during active recovery from surgery or significant injury. Evidence grades across this category are mostly C, reflecting animal data — but the practical track record is extensive.
Frequently Asked Questions
What's the difference between BPC-157 and TB-500 for injuries?
BPC-157 is better suited to local injuries — tendons, ligaments, gut lining — where it can be injected near the site and also absorbed systemically. TB-500's mechanism is inherently systemic, making it better for widespread inflammation, muscle tears, or slow-healing injuries that aren't responding to local treatment alone. In practice, they're often stacked for complex injuries because their mechanisms are complementary.
Can I take BPC-157 orally for an injury that isn't in my gut?
In rat studies, oral BPC-157 improved healing of some non-gut injuries [2], but there are no human data on oral BPC-157 for musculoskeletal injuries.
How long does it take for healing peptides to work?
These timelines come from community reports, not clinical trials: BPC-157 and TB-500 users typically report initial improvement (reduced pain, increased mobility) within 1–3 weeks of consistent use. More significant structural repair takes 4–8 weeks. GH secretagogues like Ipamorelin show measurable GH pulse increases within the first week, but cumulative recovery benefits emerge over 4–12 weeks of nightly use. Neither class provides instant healing — they accelerate the body's natural processes.
Are healing peptides appropriate to use during active training?
If you compete in a tested sport, BPC-157, TB-500, ipamorelin and CJC-1295/MOD-GRF are all prohibited by WADA at all times [1][5]. Yes — and in many cases that's the primary use case. BPC-157 and TB-500 are used both for acute injuries and as preventive/recovery tools during high training volumes. They're particularly useful for managing chronic tendon stress (common in athletes) or speeding recovery between training sessions. GH secretagogues support both recovery and muscle retention during training simultaneously.
Is there any concern about using these compounds if I've had cancer?
BPC-157 and TB-500 both have significant angiogenic activity (stimulating new blood vessel growth). This is a key mechanism for their healing effects, but it's also a theoretical concern in the context of malignancy, where angiogenesis supports tumor growth. Individuals with a history of cancer or active malignancy should discuss this carefully with an oncologist before using either compound. This is a precautionary concern, not a documented adverse finding — but it's important to be aware of.
References
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495.
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
- AJMC. FDA Panel Backs 6 Peptides for Compounding (July 2026).
- World Anti-Doping Agency. The Prohibited List (S2: peptide hormones, growth factors and related substances, including thymosin-beta-4 derivatives such as TB-500, GH secretagogues such as ipamorelin, and GHRH analogues such as CJC-1295).
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
- U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (updated April 22, 2026).
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
Related Resources
Discuss Protocols with Real Practitioners
Join the Hacksmith's Peptalk community for in-depth peptide protocol discussions, dosing Q&As, and member experiences with every compound in this guide.
Join Skool Community →Free to join · No credit card
All dosing figures are educational reference ranges from research literature. Not medical prescriptions. Discuss any protocol with a qualified healthcare provider.